Trials & Filings

Cirrus Receives MDI Grant

Kemwell unit to collaborate with FDA on formulation effects

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Cirrus Pharmaceuticals, a wholly owned subsidiary of Kemwell Biopharma Pvt. Ltd., has been awarded a grant by the FDA entitled, Comprehensive Evaluation of Formulation Effects on Metered Dose Inhaler Performance. The goals of the program are to investigate the effects of excipient concentrations and API particle size on the aerosolization performance of metered dose inhaler (MDI) formulations and to evaluate the sensitivity of in vitro methods in detecting those changes. “We are very exci...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters